A prospective, multi-center post marketing surveillance (PMS) study to monitor the safety of GlaxoSmithKline Biologicals' SA's (GSK) Meningococcal Group B (Bexsero) vaccine in Korean participants, when administered according to the prescribing information (PI) as per routine practice
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Adverse reactions
- Acronyms EPI-NEISSERIA-095 KR PMS
- Sponsors GlaxoSmithKline Biologicals
Most Recent Events
- 05 Oct 2023 New trial record